Keytruda – Page 2

IO Biotech’s cancer vaccine Cylembio narrowly misses Phase III primary endpoint in advanced melanoma, but company eyes FDA filing in 2025

4 months ago talkbio0Tagged biotech, Blackfoot language, Clinical Trials, Cylembio, Drops - Drug Form, etimupepimut, Hazard Ratio, Io satellite, Keytruda, melanoma, Overall Survival, P-Value, pembrolizumab, Phase 3, Progression-Free Survival, United States Food and Drug Administration

Cylembio; IO Biotech; melanoma; Phase 3; pivotal trial; progression-free survival (PFS); hazard ratio 0.77; p-value 0.056; Keytruda (pembrolizumab); FDA BLA; overall survival (OS) trend; IOB-013/KN-D18; NCT05155254; imsapepimut; etimupepimut; stock drop

Merck to Lay Off 6,000 Employees, Reduce Workforce by 8% in $3B Cost-Cutting Move

5 months ago talkbio0Tagged cost-cutting, Gardasil, Keytruda, layoffs, Merck, restructuring

Merck; layoffs; cost-cutting; restructuring; pharmaceuticals; job cuts; Keytruda; Gardasil; workforce reduction

Merck Announces $3 Billion Cost-Cutting and Restructuring Plan

5 months ago talkbio0Tagged Drug Industry, estate, Financial cost, Keytruda, Merck, Q2 2025, restructuring, Transection (procedure)

Merck; cost cutting; restructuring; job cuts; real estate reduction; Keytruda; pharmaceutical industry; Q2 2025 financials

Gilead Bolsters Trodelvy in Triple-Negative Breast Cancer With Practice-Changing Keytruda Combo Win

6 months ago talkbio0Tagged Antibody-Drug Conjugates, Combined Modality Therapy, Gilead Sciences, Immunotherapy, Keytruda, Phase 3 trial, practice-changing, Progression-Free Survival, TNBC, Triple Negative Breast Neoplasms, Trodelvy

Gilead Sciences; Trodelvy; Keytruda; triple-negative breast cancer; TNBC; antibody-drug conjugate; immunotherapy; progression-free survival; ASCO 2025; phase 3 trial; practice-changing; combination therapy

Bicara’s Ficerafusp Alfa Shows 46% 2-Year Survival Rate for Head and Neck Cancer Subset at ASCO 2025

7 months ago talkbio0Tagged 2025, Alfa, Antibody Therapy, ASCO, Bicara Therapeutics, Cancer of Neck, Head, Keytruda, Overall Survival, PD-L1, tumor shrinkage

ASCO 2025; Bicara Therapeutics; ficerafusp alfa; head and neck cancer; PD-L1; overall survival; antibody therapy; Keytruda; tumor shrinkage

Merus Phase 2 Data: Analysts See Strong Survival in Head & Neck Cancer, ‘Home Run’ Hopes Emerge

7 months ago talkbio0Tagged Cancer of Neck, Clinical Trials, Head, Keytruda, Merus, Overall Survival, pembrolizumab, Petosemtamab, Phase 2, Reaction, scenario

Merus; petosemtamab; Phase 2; overall survival; head and neck cancer; Pembrolizumab; Keytruda; clinical trial; analyst reaction; home run scenario

Merck’s Keytruda Achieves Industry-First Success in Preventing Head and Neck Cancer Recurrence: AACR 2025 Highlights

7 months ago talkbio0Tagged AACR, Cancer of Neck, Clinical Trials, Event-Free Survival, Head, KEYNOTE-689 trial, Keytruda, locally advanced head, Merck, pembrolizumab, perioperative, recurrence prevention, Squamous cell carcinoma, United States Food and Drug Administration

Keytruda; Merck; AACR 2025; head and neck cancer; resectable locally advanced head and neck squamous cell carcinoma; event-free survival; KEYNOTE-689 trial; perioperative pembrolizumab; recurrence prevention; clinical trial; FDA

Merck & Co. breaks ground on $1B future US home of Keytruda

8 months ago talkbio0Tagged Biological Factors, Home environment, Keytruda, Merck, United States, Wilmington

United States, Keytruda, Home environment, Merck, Wilmington, Biological Factors

‘Deviated from the core’: Akeso CEO tries to reset expectations of bispecific’s survival readout amid market tumult

8 months ago talkbio0Tagged Antibodies, Bispecific, Ivonescimab, Keytruda, Keytruda head-to-head trial, Market, Non-Small Cell Lung Carcinoma, Overall Survival, PD-1xVEGF, Reaction, summit

Ivonescimab, PD-1xVEGF bispecific antibody, Overall survival (OS) readout, Keytruda head-to-head trial, HARMONi-2 trial, Non-small cell lung cancer (NSCLC), Market reaction, Summit Therapeutics